Cue Biopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Cue Biopharma, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue9.295.491.2514.943.153.461.14
Cost of Revenue0.0040.8035.3041.3533.550.000.00
Gross Profit9.29-35.311.2514.94-30.393.460.00
Operating Expenses
Research & Development36.3040.8038.5841.3533.5527.4928.54
Selling, General & Administrative14.5916.6816.1717.3114.6512.7411.30
Operating Expenses50.7916.6854.7558.6514.65-40.2339.84
Operating Income-41.50-51.99-53.78-43.71-45.04-36.77-38.70
Other Income/Expense
Interest Income1.622.660.930.050.540.000.38
Interest Expense0.80-1.250.710.000.000.000.00
Other Income/Expense0.83-0.160.28-0.01-0.020.000.17
Income
Income Before Tax-40.67-50.73-53.01-43.67-44.58-36.29-38.16
Income Tax Expense0.000.000.000.500.210.410.83
Net Income-40.67-50.73-53.01-44.16-44.78-36.70-38.98
Net Income - Continuous Operations-40.67-50.73-53.01-44.160.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-37.53-51.44-50.49-43.67-43.99-35.55-37.94
EBIT-39.88-51.99-52.30-43.67-45.04-36.29-38.70
Depreciation & Amortization2.350.560.830.911.06-0.800.00
Earnings Per Share
Basic EPS-1.00-1.00-1.00-1.00-2.00--2.00
Diluted EPS-1.00-1.00-1.00-1.00-2.00-2.00-2.00
Basic Shares Outstanding56.3345.7535.6531.2928.6922.0420.13
Diluted Shares Outstanding56.3345.7535.6531.2928.6922.1120.13